Veracyte(VCYT.US) Director Sells US$79,683.3 in Common Stock
$Veracyte(VCYT.US)$ Director EASTHAM KARIN sold 3,870 shares of common stock on Jun 11, 2024 at an average price of $20.59 for a total value of $79,683.3.Source: Announcement What is statement of chan
Veracyte(VCYT.US) Director Sells US$78,633.76 in Common Stock
$Veracyte(VCYT.US)$ Director Bhanji Muna sold 3,870 shares of common stock on Jun 10, 2024 at an average price of $20.3188 for a total value of $78,633.76.Source: Announcement What is statement of cha
Veracyte(VCYT.US) Director Sells US$52,425 in Common Stock
$Veracyte(VCYT.US)$ Director EASTHAM KARIN sold 2,500 shares of common stock on Jun 7, 2024 at an average price of $20.97 for a total value of $52,425.Source: Announcement What is statement of changes
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?
It's Unlikely That The CEO Of Veracyte, Inc. (NASDAQ:VCYT) Will See A Huge Pay Rise This Year
Veracyte (NASDAQ:VCYT) Investors Are Sitting on a Loss of 40% If They Invested Three Years Ago
Express News | Veracyte Reports Research Using Afirma GRID Tool
Veracyte Announces That New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
Findings presented at the ENDO 2024 conference Veracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced new research findings suggesting the potential of novel molecular signatures to
Veracyte(VCYT.US) Director Sells US$32,319 in Common Stock
$Veracyte(VCYT.US)$ Director Bhanji Muna sold 1,539 shares of common stock on May 28, 2024 at an average price of $21 for a total value of $32,319.Source: Announcement What is statement of changes in
Form 144 | Veracyte(VCYT.US) Director Proposes to Sell 112.51K in Common Stocks
SEC FILLINGS DISCLOSED/ May 28, $Veracyte(VCYT.US)$ Director MUNA BHANJI intends to sell 5,409 shares of its common stock on May 28, with a total market value of approximately $112.51K. Source: Ann
Veracyte (VCYT) Fell Due to a Lack of Rising Profitability
Zacks.com Featured Highlights Include Veracyte, Signet Jewelers, UMB Financial and NVIDIA
Veracyte's (VCYT) New Findings to Advance Thyroid Cancer Care
Express News | Veracyte Announces Multiple Afirma Grid Presentations at Endo 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
Veracyte (VCYT) Up 6% Since Last Earnings: Will It Continue?
Veracyte to Participate in Upcoming Investor Conferences
Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, today announced it will participate in the following investor conferences.
An Intrinsic Calculation For Veracyte, Inc. (NASDAQ:VCYT) Suggests It's 35% Undervalued
Key Insights Using the 2 Stage Free Cash Flow to Equity, Veracyte fair value estimate is US$34.38 Veracyte is estimated to be 35% undervalued based on current share price of US$22.50 Our fair valu
Veracyte's Strong Q1 Performance and Upbeat Outlook Justify Buy Rating
Analysts Offer Insights on Healthcare Companies: Veracyte (VCYT) and Argenx Se (ARGX)
Veracyte | 10-Q: Quarterly report
No Data